DIFFERENT ANALYTICAL TECHNIQUES FOR THE ANALYSIS OF ANTICANCER DRUGS-BOSUTINIB, ENCORAFENIB AND DABRAFENIB-A REVIEW
DOI:
https://doi.org/10.22159/ijcpr.2023v15i1.2067Keywords:
Analytical methods, Anti-cancer drugs, Bosutinib, Dabrafenib, EncorafenibAbstract
In this present situation there is an increase in the number of diseases has been observed but before this drug come to market, it must undergo several procedures. The validation and analytical methods are the important techniques that help in ensuring its purity and reliability. This process involves the use of various analytical techniques to collect data about the drug. This review includes various types of analytical techniques such as ultraviolet-visible Spectrophotometric and chromatography methods such as high-performance liquid chromatography, hyphenation techniques such as LC-MS for the estimation of selected anti-cancer drugs.
Downloads
References
Nussbaumer S, Bonnabry P, Veuthey JL, Fleury Souverain S. Analysis of anticancer drugs: a review. J Talanta. 2011;85(5):2265-89. doi: 10.1016/j.com/locate/talanta85. PMID 21962644.
Arshad S, Sharif M, Naseer A. A review on cancer and anticancer drugs. Indo Am J Pharm Sci. 2016;3(11):1383-8. doi: 10.5281/zenodo.208173S.
Prakash O, Kumar A, Kumar P, Ajeet A. Anticancer potential of plants and natural products: a review. Am J Pharmacol Sci. 2013;1(6):104-15. doi: 10.12691/ajps-1-6-1.
Malviya R, Bansal V, Pal OP, Sharma PK. High-performance liquid chromatography. J Glob Pharm Technol. 2010;2(5):22-6.
Thammana M. A review on HPLC. J Pharm Anal. 2016;5(2):22-4.
de Villiers A, Lestremau F, Szucs R, Gelebart S, David F, Sandra P. Evaluation of ultra-performance liquid chromatography. Part I. Possibilities and limitations. J Chromatogr A. 2006;1127(1-2):60-9. doi: 10.1016/j.chroma.2006.05.071. PMID 16797562.
Shinde M, Kumar S, Mallik A, Jyothi N. A review on HPLC method development and validation. EPRA Int J Res Dev. 2021;6(10):92-5. doi: 10.36713/epra2016.
Ravisankar P, Gowthami S, Devlala Rao G. A review on analytical method development. Indian J Res Pharm Biotechnol. 2014;2(3):1183-94.
Kamal AH, Samah F, El-Malla, Sherin F, Hammad. A review on UV spectrophotometric methods for simultaneous multicomponent analysis. Eur J Pharm Med Res. 2016;3(2):348-60.
Shinde G, Godage RK, Jadhav RS, Manoj B, Aniket B. A review on advances in UV spectroscopy. Res J Sci Technol. 2020;12(1). doi: 10.5958/2349-2988.2020.00005.4.
Atole DM, Rajput HH. Ultraviolet spectroscopy and its pharmaceutical applications. Asian J Pharm Clin Res. 2018;2(2):59-66. doi: 10.22159/ajpcr.2018.
Behera S. UV-visible spectrophotometric method development and validation of assay of paracetamol tablet formulation. J Anal Bioanal Techniques. 2012;3(6). doi: 10.4172/2155-9872.1000151.
Devanshu S, Rahul M, Gupta A, Kishan S, Anroop N. Quantitative bioanalysis by LC-MS/MS. J Pharm Biomed Sci. 2010;7(7):1-9.
Parmar I, Patel YA. Recent method development by analytical techniques of new FDA approved drugs in 2021. Int J Curr Pharm Res. 2022;14(3):17-21.
Xu Y, Huang X, Dai S, Xiao Y, Zhou M. A simple method for the determination of bosutinib in rat plasma by UPLC-MS/MS. J Chromatogr B. 2015;1004:93-7. doi: 10.1016/j.jchromb.2015.09.030.
Yokoyama Y, Nozawa E, Morita M, Ishikawa E, Mori T, Sakurai M. Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-photodiode array detection. J Clin Lab Anal. 2022;36(8):e24598. doi: 10.1002/jcla.24598, PMID 35819095.
Mohammad AS, Ahamed F, Jayanthi B. Estimation of AntiCancer and antiviral drugs in bulk and varied dosage forms by advanced analytical techniques. World J Pharm Pharm Sci. 2018;7(10):1651-67. doi: 10.20959/wjpps201810-12570.
Chaudhari VL, Kulkarni AA. RP-HPLC method for estimation of Bosutinib in bulk form as per ICH guidelines. World J Pharm Res. 2016;5(12):417-24. doi: 10.20959/wjpr201612-7485.
Raveendranath TV, Saravanakumar RT, Male A. Stability-indicating reversed phase-ultra performance liquid chromatography method development and validation for simultaneous determination of encorafenib and binimetinib in formulation. Int J Pharm Sci Drug Res. 2020;12(5):488-94. doi: 10.25004/IJPSDR.2020.120509/index.php/ijpsdr.
Attwa MW, Darwish HW, Al-Shakliah NS, Kadi AA. A validated LC-MS/MS assay for the simultaneous quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic stability estimation. Molecules. 2021;26(9). doi: 10.3390/molecules26092717. PMID 34063139.
Suroor K, Sreedevi K. RP-HPLC method development and validation for the simultaneous estimation of encorafenib and binimetinib in API and tablet dosage form. Int J Sci Res. 2019;8(10):184-90.
Krens SD, Van der Meulen E, Jansman FGA, Burger DM, Van Erp NP. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS. Biomed Chromatogr. 2020;34(3):e4758. doi: 10.1002/bmc.4758, PMID 31758580.
Illendula S, Therisa GM. Simultaneous estimation of latest analytical method improvement and validation of dabrafenib and trametinib by means of high-performance liquid chromatography. World J Pharm Pharm Sci. 2021;10(3):1978-2004. doi: 10.20959/wjpps20213-18595.
Grover P, Bhardwaj M, Mehta L, Naved T, Handa V. Development and validation of Novel and highly sensitive stability-indicating reverse phase UPLC method for quantification of dabrafenib and its ten degradation products. Indian J Pharm Educ Res. 2022;56(3):888-98. doi: 10.5530/ijper.56.3.142.
Herbrink M, De Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM. Development and validation of a liquid chromatography–tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs. Biomed Chromatogr. 2018;32(4):e4147. doi: 10.1002/bmc.4147, PMID 29165815.
Published
How to Cite
Issue
Section
Copyright (c) 2023 RAMESH JAYAPRAKASH, ANITHA VENKATESAN, PRIYADHARSHINI VENGADHAJALAPHATH, DIVYA RAMA, ARCHANA SETTU
This work is licensed under a Creative Commons Attribution 4.0 International License.
